Association of APOE with tau-tangle pathology with and without β-amyloid

Neurobiology of Aging

Volumn 37, Issue , 2016, Pages 19-25

  Farfel, Jose M ^a,b,c   Yu, Lei ^b,c   De Jager, Philip L ^d,e,f   Schneider, Julie A ^b,c   Bennett, David A ^a,b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Apolipoprotein E; Neuropathology; Tau tangle pathology; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; APOE EPSILON2; APOE EPSILON4; APOLIPOPROTEIN E; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN REGION; COHORT ANALYSIS; CONTROLLED STUDY; DENSITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PAIRED HELICAL FILAMENT; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TAUOPATHY; VERY ELDERLY; BRAIN; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; AGING; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BRAIN; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; TAU PROTEINS;

EID: 84981741913     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.09.011     Document Type: Article

References (54)

1. Aguero-Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., Winblad, B., Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J. Clin. Epidemiol. 52 (1999), 737–743.
2. Bennett, D.A., De Jager, P.L., Leurgans, S.E., Schneider, J.A., Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology 72 (2009), 1495–1503.
3. Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Wilson, R.S., Overview and findings from the religious orders study. Curr. Alzheimer Res. 9 (2012), 628–645.
4. Bennett, D.A., Schneider, J.A., Buchman, A.S., Barnes, L.L., Boyle, P.A., Wilson, R.S., Overview and findings from the rush Memory and Aging Project. Curr. Alzheimer Res. 9 (2012), 646–663.
5. Bennett, D.A., Schneider, J.A., Wilson, R.S., Bienias, J.L., Arnold, S.E., Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 61 (2004), 378–384.
6. Berlau, D.J., Corrada, M.M., Head, E., Kawas, C.H., APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 72 (2009), 829–834.
7. Boyle, P.A., Buchman, A.S., Wilson, R.S., Kelly, J.F., Bennett, D.A., The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 34 (2010), 43–49.
8. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991), 239–259.
9. Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16 (1995), 271–278 discussion 8–84.
10. Braak, H., Del Tredici, K., Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. Acta Neuropathol. 121 (2011), 589–595.
11. Brecht, W.J., Harris, F.M., Chang, S., Tesseur, I., Yu, G.Q., Xu, Q., Dee Fish, J., Wyss-Coray, T., Buttini, M., Mucke, L., Mahley, R.W., Huang, Y., Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24 (2004), 2527–2534.
12. Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., Fagan, A.M., Morris, J.C., Mawuenyega, K.G., Cruchaga, C., Goate, A.M., Bales, K.R., Paul, S.M., Bateman, R.J., Holtzman, D.M., Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med., 3, 2011, 89ra57.
13. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The national Institute on aging, and Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol. Aging 18:4 Suppl (1997), S1–S2.
14. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993), 921–923.
15. Crary, J.F., Trojanowski, J.Q., Schneider, J.A., Abisambra, J.F., Abner, E.L., Alafuzoff, I., Arnold, S.E., Attems, J., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., Gearing, M., Grinberg, L.T., Hof, P.R., Hyman, B.T., Jellinger, K., Jicha, G.A., Kovacs, G.G., Knopman, D.S., Kofler, J., Kukull, W.A., Mackenzie, I.R., Masliah, E., McKee, A., Montine, T.J., Murray, M.E., Neltner, J.H., Santa-Maria, I., Seeley, W.W., Serrano-Pozo, A., Shelanski, M.L., Stein, T., Takao, M., Thal, D.R., Toledo, J.B., Troncoso, J.C., Vonsattel, J.P., White, C.L. 3rd, Wisniewski, T., Woltjer, R.L., Yamada, M., Nelson, P.T., Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128 (2014), 755–766.
16. Fagan, A.M., Watson, M., Parsadanian, M., Bales, K.R., Paul, S.M., Holtzman, D.M., Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9 (2002), 305–318.
17. Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., van Duijn, C.M., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997), 1349–1356.
18. Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975), 189–198.
19. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
20. Huang, Y., Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 16 (2010), 287–294.
21. Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V., Montine, T.J., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's Demen. 8 (2012), 1–13.
22. Jack, C.R. Jr., PART and SNAP. Acta Neuropathol. 128 (2014), 773–776.
23. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9 (2010), 119–128.
24. Jack, C.R. Jr., Vemuri, P., Wiste, H.J., Weigand, S.D., Aisen, P.S., Trojanowski, J.Q., Shaw, L.M., Bernstein, M.A., Petersen, R.C., Weiner, M.W., Knopman, D.S., Alzheimer's Disease Neuroimaging Initiative. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 68 (2011), 1526–1535.
25. James, B.D., Leurgans, S.E., Hebert, L.E., Scherr, P.A., Yaffe, K., Bennett, D.A., Contribution of Alzheimer disease to mortality in the United States. Neurology 82 (2014), 1045–1050.
26. Jellinger, K.A., Alafuzoff, I., Attems, J., Beach, T.G., Cairns, N.J., Crary, J.F., Dickson, D.W., Hof, P.R., Hyman, B.T., Jack, C.R. Jr., Jicha, G.A., Knopman, D.S., Kovacs, G.G., Mackenzie, I.R., Masliah, E., Montine, T.J., Nelson, P.T., Schmitt, F., Schneider, J.A., Serrano-Pozo, A., Thal, D.R., Toledo, J.B., Trojanowski, J.Q., Troncoso, J.C., Vonsattel, J.P., Wisniewski, T., PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 129 (2015), 757–762.
27. Jellinger, K.A., Attems, J., Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol. 113 (2007), 107–117.
28. Jiang, Q., Lee, C.Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T.M., Collins, J.L., Richardson, J.C., Smith, J.D., Comery, T.A., Riddell, D., Holtzman, D.M., Tontonoz, P., Landreth, G.E., ApoE promotes the proteolytic degradation of Abeta. Neuron 58 (2008), 681–693.
29. Klein, W.L., Stine, W.B. Jr., Teplow, D.B., Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 (2004), 569–580.
30. Koffie, R.M., Hashimoto, T., Tai, H.C., Kay, K.R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K.J., Frosch, M.P., Lee, V.M., Holtzman, D.M., Hyman, B.T., Spires-Jones, T.L., Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135:Pt 7 (2012), 2155–2168.
31. LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., Frail, D.E., Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269 (1994), 23403–23406.
32. Liu, L., Drouet, V., Wu, J.W., Witter, M.P., Small, S.A., Clelland, C., Duff, K., Trans-synaptic spread of tau pathology in vivo. PloS one, 7, 2012, e31302.
33. Ma, J., Yee, A., Brewer, H.B. Jr., Das, S., Potter, H., Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372 (1994), 92–94.
34. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., Vogel, F.S., Hughes, J.P., van Belle, G., Berg, L., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991), 479–486.
35. Mungas, D., Tractenberg, R., Schneider, J.A., Crane, P.K., Bennett, D.A., A 2-process model for neuropathology of Alzheimer's disease. Neurobiol. Aging 35 (2014), 301–308.
36. Nag, S., Yu, L., Capuano, A.W., Wilson, R.S., Leurgans, S.E., Bennett, D.A., Schneider, J.A., Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer's Disease. Ann. Neurol. 77 (2015), 942–952.
37. Nagy, Z., Esiri, M.M., Jobst, K.A., Johnston, C., Litchfield, S., Sim, E., Smith, A.D., Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69 (1995), 757–761.
38. Nelson, P.T., Abner, E.L., Schmitt, F.A., Kryscio, R.J., Jicha, G.A., Santacruz, K., Smith, C.D., Patel, E., Markesbery, W.R., Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J. Neuropathol. Exp. Neurol. 68 (2009), 774–784.
39. Nicoll, J.A., Savva, G.M., Stewart, J., Matthews, F.E., Brayne, C., Ince, P., Medical Research Council Cognitive Function and Ageing Study. Association between APOE genotype, neuropathology and dementia in the older population of England and Wales. Neuropathol Appl. Neurobiol. 37 (2011), 285–294.
40. Ohm, T.G., Kirca, M., Bohl, J., Scharnagl, H., Gross, W., Marz, W., Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 66 (1995), 583–587.
41. Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinisto, L., Halonen, P., Kontula, K., Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. New Engl. J. Med. 333 (1995), 1242–1247.
42. Rait, G., Walters, K., Bottomley, C., Petersen, I., Iliffe, S., Nazareth, I., Survival of people with clinical diagnosis of dementia in primary care: cohort study. BMJ, 341, 2010, c3584.
43. Royall, D.R., Palmer, R.F., The temporospatial evolution of neuritic plaque-related and independent tauopathies: implications for dementia staging. J. Alzheimer's Dis. 40 (2014), 541–549.
44. Royall, D.R., Palmer, R.F., Petrovitch, H., Ross, G.W., Masaki, K., White, L.R., Modeling regional vulnerability to Alzheimer pathology. Neurobiol. Aging 33 (2012), 1556–1563.
45. Sabbagh, M.N., Malek-Ahmadi, M., Dugger, B.N., Lee, K., Sue, L.I., Serrano, G., Walker, D.G., Davis, K., Jacobson, S.A., Beach, T.G., The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease. BMC Neurol., 13, 2013, 44.
46. Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H., Pericak-Vance, M.A., Goldgaber, D., Roses, A.D., Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 9649–9653.
47. Schneider, J.A., Arvanitakis, Z., Yu, L., Boyle, P.A., Leurgans, S.E., Bennett, D.A., Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 135:Pt 10 (2012), 3005–3014.
48. Schneider, J.A., Bienias, J.L., Wilson, R.S., Berry-Kravis, E., Evans, D.A., Bennett, D.A., The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke 36 (2005), 954–959.
49. Sen, A., Alkon, D.L., Nelson, T.J., Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. J. Biol. Chem. 287 (2012), 15947–15958.
50. Sharman, M.J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I.J., Lim, W.L., Singh, S., Wenk, M.R., Ghiso, J., Buxbaum, J.D., Gandy, S., Martins, R.N., APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J. Alzheimer's Dis. 21 (2010), 403–409.
51. Tschanz, J.T., Corcoran, C., Skoog, I., Khachaturian, A.S., Herrick, J., Hayden, K.M., Welsh-Bohmer, K.A., Calvert, T., Norton, M.C., Zandi, P., Breitner, J.C., Cache County Study Group. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology 62 (2004), 1156–1162.
52. Yamada, M., Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 23 (2003), 311–317.
53. Yoshiyama, Y., Uryu, K., Higuchi, M., Longhi, L., Hoover, R., Fujimoto, S., McIntosh, T., Lee, V.M., Trojanowski, J.Q., Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model. J. Neurotrauma 22 (2005), 1134–1141.
54. Yu, L., Boyle, P.A., Leurgans, S., Schneider, J.A., Bennett, D.A., Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol. Aging 35 (2014), 819–826.